Bausch + Lomb shares are higher as traders position ahead of the company’s next catalyst—first-quarter 2026 results scheduled for April 29, 2026—and lean into the company’s 2026 outlook that points to steady top-line growth and expanding profitability. The setup is largely “pre-earnings positioning”: incremental buyers are stepping in after the company’s most recent guidance reset expectations for 2026 performance.

The company’s latest full-year 2026 framework calls for revenue of about $5.375 billion to $5.475 billion and adjusted EBITDA of $1.0 billion to $1.05 billion. That implies a margin profile investors can underwrite now, particularly if operating discipline and mix improvements continue through the year—key ingredients for a higher-quality earnings narrative into the upcoming quarter.

With the next earnings date approaching, even modest changes in sentiment can translate into a sharper one-day move, especially when the market is leaning toward “better-than-feared” outcomes rather than a confirmed new headline. Short positioning is also notable (recently around the high-single-digit percent range of float in some market snapshots), which can amplify upside when the stock starts to trend higher into an event window.

The next major check-in is April 29, 2026, when investors will look for confirmation that demand trends in eye health remain resilient and that profitability is tracking toward the company’s 2026 targets. Watch for commentary on product momentum across Vision Care, Ophthalmic Pharmaceuticals, and Surgical, plus any updates that tighten the timeline toward the 2026 plan.